NO20076360L - Dengue serotype 2 attenuert stamme - Google Patents

Dengue serotype 2 attenuert stamme

Info

Publication number
NO20076360L
NO20076360L NO20076360A NO20076360A NO20076360L NO 20076360 L NO20076360 L NO 20076360L NO 20076360 A NO20076360 A NO 20076360A NO 20076360 A NO20076360 A NO 20076360A NO 20076360 L NO20076360 L NO 20076360L
Authority
NO
Norway
Prior art keywords
dengue serotype
attenuated strain
strain
vdv2
dengue
Prior art date
Application number
NO20076360A
Other languages
English (en)
Inventor
Richard Kinney
Claire Huang
Veronique Barban
Jean Lang
Bruno Guy
Original Assignee
Ct S For Disease Control And P
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct S For Disease Control And P filed Critical Ct S For Disease Control And P
Publication of NO20076360L publication Critical patent/NO20076360L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/08—Inactivation or attenuation by serial passage of virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24164—Methods of inactivation or attenuation by serial passage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Oppfinnelsen angår levende svekkede VDV2- (VERO-avledet vaksine Dengue serotype 2) stammer som er avledet fra villtype dengue-2-stamme 16681 ved passering på PDK- og Vero-celler. Oppfinnelsen angår videre et vaksinepreparat som omfatter en VDV2-stamme.
NO20076360A 2005-06-17 2007-12-12 Dengue serotype 2 attenuert stamme NO20076360L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69127405P 2005-06-17 2005-06-17
PCT/IB2006/001513 WO2006134443A1 (en) 2005-06-17 2006-06-07 Dengue serotype 2 attenuated strain

Publications (1)

Publication Number Publication Date
NO20076360L true NO20076360L (no) 2008-03-11

Family

ID=37103341

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076360A NO20076360L (no) 2005-06-17 2007-12-12 Dengue serotype 2 attenuert stamme

Country Status (18)

Country Link
US (4) US7641908B2 (no)
EP (1) EP1891210B1 (no)
JP (1) JP5075120B2 (no)
KR (2) KR20080018271A (no)
CN (1) CN101238209B (no)
AR (1) AR053914A1 (no)
AT (1) ATE475706T1 (no)
AU (1) AU2006257621B2 (no)
BR (1) BRPI0613287A2 (no)
CA (1) CA2611954C (no)
DE (1) DE602006015807D1 (no)
IL (1) IL188068A0 (no)
MX (1) MX2007015872A (no)
MY (2) MY144542A (no)
NO (1) NO20076360L (no)
TW (1) TWI375722B (no)
WO (1) WO2006134443A1 (no)
ZA (1) ZA200710752B (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0613287A2 (pt) * 2005-06-17 2010-12-28 Sanofi Pasteur cepa do vìrus da dengue-2 vivo atenuada, composição imunogênica, composição de vacina, ácido nucléico isolado, poliproteìna isolada codificadas pela seq id n .1 ou fragmentos desta e fragmento da poliproteìna
CU23586A1 (es) * 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
CN101139638B (zh) * 2007-05-08 2010-05-26 深圳太太基因工程有限公司 一种用于检测登革病毒ⅲ型核苷酸片段的引物和探针序列
ES2615390T3 (es) 2008-03-05 2017-06-06 Sanofi Pasteur Proceso para estabilizar una composición de vacuna que contiene adyuvante
EP2143440A1 (fr) 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
US8968996B2 (en) * 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
NZ597000A (en) * 2009-06-01 2014-07-25 Takeda Vaccines Inc Compositions and methods for administration of vaccines against dengue virus
EP2473624B1 (en) 2009-08-31 2019-05-01 Gen-Probe Incorporated Dengue virus assay
CN102755642B (zh) * 2012-07-13 2014-01-08 中国食品药品检定研究院 一种炭疽疫苗的制备方法
KR20150036593A (ko) * 2012-07-24 2015-04-07 사노피 파스퇴르 뎅기열 바이러스 감염 예방용 백신 조성물
MX381497B (es) 2012-07-24 2025-03-12 Sanofi Pasteur Composiciones vacuna.
BR112015012515B1 (pt) 2012-11-30 2023-04-11 Sanofi Pasteur Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola
JP2016504315A (ja) 2012-12-14 2016-02-12 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. 三価デングウイルス製剤に関する組成物、投与方法および使用
HRP20231581T1 (hr) 2013-03-15 2024-03-15 Takeda Vaccines, Inc. Pripravci i postupci za kimerne konstrukte virusa denga groznice u cjepivima
BR112015031226A2 (pt) 2013-06-21 2017-08-29 Merck Sharp & Dohme Composição de vacina, e, uso da composição de vacina
CN103382509A (zh) * 2013-07-17 2013-11-06 浙江国际旅行卫生保健中心 逆转录-环介导等温扩增检测登革2型病毒的试剂及检测方法
TWI852899B (zh) 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
EP3236997B1 (en) 2014-12-22 2024-05-29 Merck Sharp & Dohme LLC Dengue virus vaccine compositions and methods of use thereof
BR112017028212A2 (pt) 2015-07-03 2018-09-11 Sanofi Pasteur vacinação concomitante contra dengue e febre amarela
EP3382012A4 (en) 2015-11-27 2019-07-03 KM Biologics Co., Ltd. LIVING VIRUS WITH A BANK OF ATTENUATED TREES OF DENGUEVIRUS AND DENGUE VACCINE THEREFORE AS ANTIGENE
CN105999260B (zh) * 2016-05-13 2019-12-10 四川大学 氢氧化铝凝胶-氯化钠复合免疫佐剂及其制备方法和用途
SG11202002933TA (en) 2017-10-05 2020-04-29 Sanofi Pasteur Compositions for booster vaccination against dengu
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
WO2020051334A1 (en) 2018-09-05 2020-03-12 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6093296A (en) * 1995-06-07 1996-12-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Infectious dengue 2 virus pdk-53 as quadravalent vaccine
JP2002540168A (ja) * 1999-03-26 2002-11-26 ウォルター リード アーミー インスティテュート オブ リサーチ 多価デングウイルスワクチン
ATE412738T1 (de) * 2000-05-30 2008-11-15 Univ Mahidol Attenuierte stammen von denguevirus und ihre verwendungen in impfstoffzusammensetzungen
US7494659B2 (en) 2000-09-25 2009-02-24 Polymun Scientific Immunbiologische Forschung Gmbh Live attenuated influenza vaccine
DK2290109T3 (da) * 2001-05-22 2014-11-10 Us Gov Health & Human Serv Udvikling af mutationer, der er anvendelige til svækkelse af dengue-vira samt kimære dengue-vira
ATE481982T1 (de) * 2002-05-03 2010-10-15 Us Gov Health & Human Serv Dengue-vakzine mit einer gemeinsamen 30 nukleotid-deletion im 3'-utr der dengue-typen 1 und 2.
BRPI0613287A2 (pt) * 2005-06-17 2010-12-28 Sanofi Pasteur cepa do vìrus da dengue-2 vivo atenuada, composição imunogênica, composição de vacina, ácido nucléico isolado, poliproteìna isolada codificadas pela seq id n .1 ou fragmentos desta e fragmento da poliproteìna

Also Published As

Publication number Publication date
US8795688B2 (en) 2014-08-05
IL188068A0 (en) 2008-03-20
CN101238209A (zh) 2008-08-06
EP1891210A1 (en) 2008-02-27
CA2611954A1 (en) 2006-12-21
KR20080018271A (ko) 2008-02-27
DE602006015807D1 (de) 2010-09-09
AU2006257621A1 (en) 2006-12-21
US7641908B2 (en) 2010-01-05
US20120083585A1 (en) 2012-04-05
ATE475706T1 (de) 2010-08-15
CA2611954C (en) 2014-01-28
MY161457A (en) 2017-04-14
MY144542A (en) 2011-09-30
EP1891210B1 (en) 2010-07-28
US20070026016A1 (en) 2007-02-01
US20100174057A1 (en) 2010-07-08
MX2007015872A (es) 2008-04-21
US8067566B2 (en) 2011-11-29
CN101238209B (zh) 2013-02-13
TW200738881A (en) 2007-10-16
ZA200710752B (en) 2008-12-31
US20150031857A1 (en) 2015-01-29
KR101582163B1 (ko) 2016-01-05
TWI375722B (en) 2012-11-01
AU2006257621B2 (en) 2011-08-11
KR20140019034A (ko) 2014-02-13
JP5075120B2 (ja) 2012-11-14
AR053914A1 (es) 2007-05-23
BRPI0613287A2 (pt) 2010-12-28
JP2008546383A (ja) 2008-12-25
WO2006134443A1 (en) 2006-12-21

Similar Documents

Publication Publication Date Title
NO20076360L (no) Dengue serotype 2 attenuert stamme
NO20076355L (no) Dengue serotype 1 attenuert stamme
HUS2500008I1 (hu) Alfa-2,3- és alfa-2,6 szializációt tartalmazó rekombináns FSH
NO2019004I1 (no) patisiran: dekket gjennom sekvensene i kravene 1, 8 og 9 (se særlig krav 8 (b) og (c) i patentet. Det vises også til følgebrevet til søknaden.
SG159542A1 (en) Compositions against sars-coronavirus and uses thereof
MX341204B (es) Metodo para caracterizar almenos un microorganismo por medio de espectrometria de masa.
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
DK1776011T3 (da) Fungicid sammensætning, indeholdende et syreamidderivat
AR059445A1 (es) Composiciones de antimicoticos ramnolipidicos y metodos de uso relacionados
NO20074885L (no) N-proteinmutanter av porcinreproduktive og andedrettssyndromvirus
NO20082704L (no) Hepatitt C virusvarianter
DK1965809T3 (da) Præparater til forbedring af sundhedstilstanden i dyrs tarmsystem og dyrs ydeevne omfattende Beta-glucanerne og Alfa-fucaner
CL2008000518A1 (es) Composicion de control de plagas que comprende etofenprox y un compuesto desinfectante seleccionado entre flusulfamida, himexazol, simeconazol, y pentiopirad; y metodo de prevencion del dano producido por plagas.
EA200702193A1 (ru) Гликозилирование белков
IL187915A0 (en) 1,2-di(cyclic group)substituted benzene derivative
WO2007034395A3 (en) Luminescence sensor comprising at least two wire grids
EA200801297A1 (ru) Способ снижения уровня постпрандиальной глюкозы
FR2922211B1 (fr) Peptides cycliques comprenant au moins un residu azabeta3 aminoacycle et leurs utilisations
BRPI0615384B8 (pt) composições oftálmicas de cetotifeno estabilizadas e conservadas
WO2008058706A3 (de) Enterococcus faecalis- und/oder enterococcus faecium-antigen
TW200801188A (en) Method to remove bisulfite by-products from enzyme compositions
TR200805195T1 (tr) Antep fıstığı dal güvesi, kermania pistaciella'nın (lepidoptera: oinophilidae) davranışını etkilemeye dönük kimyasallara ait bileşim.
吳起燻 Kaburo related story on Heikemonogatari
WO2008034003A3 (en) Imaging compositions, imaging methods, and imaging members
TH85805B (th) สายพันธุ์ที่ถูกทำให้อ่อนฤทธิ์ของไข้เลือดออกซีโรไทป์ 2

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application